Copper Balance

Monopar Therapeutics presented Phase 2 data on ALXN1840 for Wilson disease at AASLD 2025. The study (n=8) demonstrated a significant reduction in mean daily copper balance, driven by increased fecal copper excretion, in patients treated with ALXN1840 compared to baseline. Improvement was observed during both initial and sustained dosing periods. While promising, the small sample size warrants further investigation. Presentation materials and the abstract are available on Monopar’s and AASLD’s websites, respectively.